Standalone and Consolidated Financial Results
QUICKHEAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Quick Heal Technologies reported a significant deterioration in FY26 performance. Consolidated revenue declined 6.6% year-on-year to ₹261 Cr, while the company swung into a net loss of ₹10.9 Cr compared to a profit of ₹5.0 Cr in FY25. Q4 FY26 was particularly weak with revenue falling 25% YoY to ₹48.7 Cr and a net loss of ₹19.9 Cr. EBITDA turned deeply negative at -₹29.4 Cr for the full year versus -₹6.6 Cr in FY25, with EBITDA margin compressing sharply to -11.3% from -2.4%. The company attributed the decline to headwinds in the consumer vertical (hardware price rises, industry degrowth, and tightened credit controls) while enterprise revenue grew 22.5% to ₹148.4 Cr. Operating cash flow did improve to +₹15.4 Cr from -₹22.3 Cr in the prior year. Statutory auditors issued an unmodified (clean) opinion.
The company is in loss-making territory with a sharp decline in profitability metrics, which is negative for shareholders. The enterprise business showed resilience but is not yet large enough to offset consumer weakness. The stock likely faces near-term pressure given the significant miss.